Tislelizumab, a programmed cell death-1 inhibitor approved for multiple malignancies, may induce Stevens-Johnson syndrome/toxic epidermal necrolysis (SJS/TEN)—a rare but potentially fatal severe drug eruption—and early effective intervention is pivotal for reducing SJS/TEN-related mortality. This evidence concerns the gene PDCD1 and toxic epidermal necrolysis.